A Psilocybin Experience Gone Wrong: The Importance of Psychedelic Assisted Psychotherapy
Journal of Psychoactive Drugs – January 07, 2025
Source: OpenAlex
Summary
A single patient's adverse psilocybin experience, a powerful hallucinogen, without a guiding psychotherapist resulted in inpatient psychiatry admission. This case, pivotal for Psychology and Psychedelics and Drug Studies, emphasizes the necessity of controlled settings. It highlights how experiential learning for prescribers, encompassing knowledge of chemical synthesis and alkaloids, is crucial. Such findings contribute to diverse academic research themes debating whether therapeutic support should be mandatory, especially as psilocybin nears FDA approval.
Abstract
As psilocybin awaits approval by the Food and Drug Administration (FDA), scholars debate whether psychedelic-assisted psychotherapy should be required when prescribing this medicine. Here, we report the case of a patient who underwent a psilocybin experience without psychedelic-assisted psychotherapy, resulting in inpatient psychiatric admission. This case underscores the importance of taking psilocybin in controlled clinical settings. Moreover, we discuss how psychedelic-assisted psychotherapy could have altered the outcome of her experience and the role of experiential learning in psychedelics for potential prescribers.